Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Substance Use Disorders (Upcoming)
Clonal Hematopoiesis (Upcoming)
Sex Differences in Medicine (Upcoming)
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Medicine
Research Letters
Letters to the Editor
Editorials
Commentaries
Reviews
Viewpoints
Top read articles
Clinical Medicine
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Brian J. Druker, Nicholas B. Lydon
Brian J. Druker, Nicholas B. Lydon
Published January 1, 2000
Citation Information:
J Clin Invest.
2000;
105(1)
:3-7.
https://doi.org/10.1172/JCI9083
.
View:
Text
|
PDF
Perspective
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Text
PDF
Abstract
Authors
Brian J. Druker, Nicholas B. Lydon
×
Figure 3
Options:
View larger image
(or click on image)
Download as PowerPoint
Model of STI 571 bound within the active site of the Abl kinase. (
a
) Overlay of ATP (red) and STI 571 (orange). Key amino acids that interact with ATP are shown. Binding mode of STI 571 shown from above (
b
) and from the side (
c
).